In 2022, Dr. Aramini designed and conducted a groundbreaking case series study in Canada, using research-quality oral medications, compounded at a pharmacy in Ontario, and overseen by a Licensed Ontario DMV. Between November 2022 and April 2025, Dr. Aramini treated over 600 cases of FIP as part of his trial. Every cat followed the same protocol, combining GS-4431524 and Mefloquine to limit GS-441524 resistance and relapses/treatment failure.
Join us on Wednesday, January 21 at 7:00 PM EST for a webinar hosted by Clearpoint Pharmacy, featuring our Founder, Dr. Jeff Aramini, who will share his expertise, clinical insights, and experiences from this groundbreaking study with the veterinary community.
At the end of this session, participants will be able to:
- Recognize the significance of using “response to GS-441524” as a diagnostic test for FIP.
- Understand the importance of starting FIP treatment with GS-441524 as soon as there is a tentative diagnosis.
- Be able to apply proper and consistent dosing of GS-441524 and Mefloquine to ensure therapeutic effectiveness.
- Identify the various supportive treatments essential to ensuring the success of the FIP treatment protocol, in particular in the early phases of treatment.
📅 Wednesday, January 21, 2026
🕖 7:00 PM EST
🗒️ Event Page
